Discounted Cash Flow (DCF) Analysis Unlevered

Ocuphire Pharma, Inc. (OCUP)

$3.5

0.00 (0.00%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 3.5 | undervalue

Operating Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Revenue (%)
EBITDA --------
EBITDA (%)
EBIT --------
EBIT (%)
Depreciation --------
Depreciation (%)

Balance Sheet Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash --------
Total Cash (%)
Account Receivables --------
Account Receivables (%)
Inventories --------
Inventories (%)
Accounts Payable --------
Accounts Payable (%)
Capital Expenditure --------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 3.5
Beta -0.059
Diluted Shares Outstanding 14.85
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 0.37%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.334
Total Debt 0.54
Total Equity 51.98
Total Capital 52.52
Debt Weighting 1.02
Equity Weighting 98.98
Wacc

Build Up Free Cash

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
EBITDA --------
EBIT --------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT --------
Depreciation --------
Accounts Receivable --------
Inventories --------
Accounts Payable --------
Capital Expenditure -0.03-------
UFCF --------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.30
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -24
Equity Value -
Shares Outstanding 14.85
Equity Value Per Share -